Microbiota, Pulmonary Disease, Chronic Obstructive
Conditions
Keywords
Chronic obstructive pulmonary disease, Microbiome
Brief summary
This study is to build a microbiome cohort by collecting sputum and fecal samples every few months for three years from healthy smokers and chronic obstructive pulmonary disease (COPD) patients. The aim of this study is to analyze the composition of microbiome of various samples (e.g. sputum, feces) and describe the difference between healthy smokers and COPD patients.
Detailed description
After the introduction of the gut-lung axis theory, extensive studies revealed the diversity of microbiomes among healthy smokers and COPD patients form the respiratory samples or lung tissues. In the previous study, distinct difference in composition of microbiome in lung tissue between healthy smokers and COPD patients was reported. This study is to build a microbiome cohort by collecting sputum and fecal samples every few months for three years from healthy smokers and chronic obstructive pulmonary disease (COPD) patients who are being followed up by Asan Medical Center. The aim of this study is to analyze the composition of microbiome of various samples (e.g. sputum, feces) and describe the difference between healthy smokers and COPD patients. This study would help establishing gut-lung axis model in humans.
Interventions
DIAGNOSTIC_TESTObtain samples from sputum and feces
Samples are obtained from participants. No further intervention is required. Obtained samples will be further analyzed.
Sponsors
Asan Medical Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Patients with smoking history at least 10 pack-year * Patients with persistent airflow limitation that was not fully reversible (e.g. post-bronchodilator forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) \<0.7)
Exclusion criteria
* Patients with co-existing illness that would interfere with study results (e.g., malignancy, congestive heart failure, cerebrovascular disorders, chronic renal failure, diabetes with severe complications, or uncontrolled hypertension) * Patients with respiratory disease other than obstructive lung disease (e.g., previous pulmonary resection, tuberculosis-destroyed lung, and bronchiectasis)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Alpha diversity measured by operational taxonomic unit (OTU) quantitative analysis | An average of 3 months | DNA is extracted from each sample from each patient by using a DNA Isolation Kit. The 16S universal primers are used for amplification of 16S ribosomal ribonucleic acid (rRNA) genes with polymerase chain reaction (PCR) system. After amplication, sequencing is performed using the GREENGENES database, after which a metagenomic analysis was performed by the MD Healthcare corporation using MDx-Pro software (Ver.1, Seoul, South Korea). Taxonomic assignment of these sequences is carried out with an operational taxonomic unit (OTU) cutoff of 3%. |
| Microbiome composition by metagenomic analysis | An average of 3 months | The composition of microbiome is presented as bar graph. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Biodiversity described by the Shannon diversity index and the Simpson index | An average of 3 months | The Shannon index and the Simpson index is calculated by using metagenomic data. |
| Biodiversity described by Principal Component Analysis (PCA) | An average of 3 months | PCA is performed for all 16S rRNA gene reads clustered at a 97% similarity. |
Countries
South Korea
Contacts
Primary ContactSei Won Lee, M.D. Ph.D.
Outcome results
None listed